Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-613 in Acute Gout
NCT06169891Phase 3Not yet recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of SSGJ-613 in gout, sponsored by 3S Guojian Pharmaceutical. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
SSGJ-613
03
Conditions
gout
Beyond the preview
Go deeper on NCT06169891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169891.